Glow

Where the name "Glow" comes from

"Glow" is a name the peptide community coined for a three-part combination aimed at skin: GHK-Cu, BPC-157, and TB-500. Peptide Health Lab neither coined it nor endorses it. This page exists because the name is what people search for, and a page that describes what the name refers to is more useful than pretending the term does not exist.

The origin is not documented anywhere in the published literature. There is no paper that proposes the combination, no clinic protocol in a journal that introduced it, and no consistent definition. The component list drifts between online sources, with some versions adding or dropping a peptide. What is described here is the three-component version the name most often refers to. A 2026 narrative review of peptides in sports medicine describes the surrounding dynamic directly: use of these compounds is driven by patient demand rather than by an evidence base, and social media amplifies the placebo response that makes an unstudied combination feel like it worked.^[10]

A name is not a finding. Everything below is organized around what was actually measured, in what species, by what route.

What's in it and why people combine them

GHK-Cu is the component the name is about. It is a naturally occurring tripeptide with a high affinity for copper(II), and it has one of the longest mechanistic paper trails in this field. It stimulated collagen synthesis in cultured human fibroblasts beginning between 10⁻¹² and 10⁻¹¹ M and peaking near 10⁻⁹ M, with no change in cell number, and the GHK sequence occurs in the α2(I) chain of type I collagen itself, which is where the idea that it is a wound signal released by proteolysis comes from.^[1] In keratinocytes and in skin-equivalent models it increased proliferation, integrin α6 and β1 expression, and p63 positivity, which is the basis for the claim that it supports basal stem cells.^[2]

BPC-157 is the repair component. Its rodent literature is not limited to tendon and gut: topical treatment accelerated closure in an alkali-burn skin model, with better granulation tissue, re-epithelialization, dermal remodeling, and collagen deposition than controls at eighteen days, and it increased endothelial proliferation, migration, and tube formation in culture.^[6]

TB-500 carries a reputation that belongs to a larger molecule. The dermal work people cite for it was done on thymosin β4, the full 43-amino-acid protein: preclinical acceleration of dermal healing across several animal models, and phase 2 trials in pressure ulcers, stasis ulcers, and epidermolysis bullosa wounds.^[8] TB-500 is a seven-residue fragment of that protein. No published study has compared the fragment with the parent protein head to head.

The rationale for putting them together is mechanistic layering: matrix signalling from one, angiogenesis and granulation from another, cell migration from a third. That is a story about mechanisms. It is not a result.

What the evidence says about the combination

No published study has evaluated GHK-Cu, BPC-157, and TB-500 together, for any endpoint, in any species. That is a statement about a literature search, not an assumption: searching for the components in combination returns reviews that discuss each of them separately and nothing that tested them together.^[10]

One published study bears on two of the three. Thirty-two rats underwent Achilles tendon transection and repair and were randomized to control, BPC-157, TB-500, or both peptides for four weeks. TB-500 alone reached statistical significance for maximum load to failure and for the histopathological scores; BPC-157 alone was numerically better without reaching significance; and the combined arm did not confer any additional benefit over either agent alone. The authors suggest the two may converge on shared downstream pathways, and say that hypothesis needs testing.^[9] It is a small, exploratory, four-week rat tendon study. Not a skin study, and not a study of this combination. It is also the only published test of additivity between any two components of Glow, and its answer was no.

That is why the combination claim on this page is graded as anecdotal. Two of the three components have a great deal of literature behind them. The combination itself has never been the subject of any.

Where the evidence is weak

The route in the human data is not the route in the stack. The single randomized human aesthetic trial of GHK-Cu applied it to the skin as a cosmetic regimen after laser resurfacing. The combination people mean by "Glow" is injected. Nothing in the published human record speaks to the injected form of this peptide for an appearance endpoint.

That one randomized human trial was negative on everything measured objectively. Thirteen patients completed it. Blinded evaluators and computer image analysis found no significant difference in resolution of erythema, and objective assessment found no significant improvement in wrinkles or overall skin quality. The only endpoint that separated was the patients' own satisfaction questionnaire.^[4] A subjective endpoint improving while every objective one does not is the exact pattern a placebo-sensitive intervention produces.

The most-cited GHK reviews are proponent literature. The widely quoted review of GHK in skin regeneration is written by the peptide's principal long-term proponent and his commercial research group, and it collects cosmetic and in vitro claims, up to and including the assertion that the peptide can reset gene expression to a healthier state, into a single narrative that reads much stronger than the underlying primary studies.^[5] It is a legitimate starting point for the mechanism. It is not evidence of an outcome, and its framing should be read with the authorship in mind.

Animal wound models are not cosmetic outcomes. The strongest in vivo result for the copper tripeptide is faster closure of surgically created wounds inside an ischemic flap in rats.^[3] Healing an impaired wound faster and improving the appearance of intact skin are different claims with different endpoints, and the second one has not been demonstrated.

Three weak bases do not sum to a strong one. Combining compounds whose evidence is animal-only produces a combination whose evidence is animal-only. Where the additivity question has actually been asked between two of these components, the answer was that there was no added benefit.^[9]

Long-term safety is unstudied. Nothing in the published record addresses repeated or prolonged exposure to any of these compounds in a healthy person using them for appearance, and the shared proposed mechanism across all three is angiogenesis.^[10]

Questions to bring to a provider

The useful version of this conversation is not "is Glow worth trying." It is "here is what I want my skin to do, and here is what has actually been shown to do it."

• What is the actual concern: texture, laxity, pigmentation, scarring, a healing wound? And what does the standard-of-care evidence offer for that specific thing?
• Given that the one randomized human trial of topical GHK-Cu found no objective difference from control, what would have to be true for an injected version to do more?^[4]
• If the reasoning rests on thymosin β4's healing trials, how does the fact that those trials used a different, larger molecule change it?^[7]
• Does a personal or family history of malignancy change the calculus, given that angiogenesis is the shared proposed mechanism?^[6]
• Which objective measure would show whether anything actually changed, rather than how it looks in a different mirror? Standardized photography, a validated scale, a clinician assessment at a fixed interval?

Anti-doping status

Two of the three components of this combination are prohibited in tested sport at all times, in and out of competition, under the World Anti-Doping Agency Prohibited List in force for 2026:

• BPC-157: section S0, non-approved substances. S0 covers any pharmacological substance not addressed by another section of the List and with no current approval by any governmental regulatory health authority for human therapeutic use; BPC-157 is named there as an example. Substances in this class are Specified Substances.
• TB-500: section S2.3, growth factors and growth factor modulators. The List names "thymosin-β4 and its derivatives" and gives TB-500 as the example. Substances in the S2 class are non-Specified Substances, which carries different sanctioning consequences from S0.

GHK-Cu is not named anywhere on the 2026 List. That is not the same as being permitted. S0 is defined by criteria rather than by its examples: the section reads on any pharmacological substance without current approval for human therapeutic use that is not addressed elsewhere. An athlete should treat a non-approved injectable peptide as a question for their national anti-doping organization rather than as a settled absence.

The statuses above were read from the published Prohibited List itself, not from the research literature, because the research literature has carried this wrongly: a 2025 review of BPC-157 states in its own abstract that the compound was only temporarily banned and is not currently listed, which is false, and that sentence is the origin of a claim that still circulates. Reviews are a source for what the literature shows and are never a source for what a regulator has done.^[10] The List is reissued annually and sections renumber, so a competing athlete should confirm the current year's list rather than this page.